Article
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Leukemia research - 1 Sept 2011
Ustun Celalettin, DeRemer David L, Akin Cem
Abstract excerpt
Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KIT(D816V)). A small subset of SM patients with KIT(D816V) mutation require cytoreductive therapy. In these patients, tyrosine kinase inhibitors (TKIs) have been actively investigated over the last decade because of codon 816 KIT mutations causing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.